Anton Rx Report

How well do you understand cell based therapy? It’s complicated! Given the pace of research and the number of already approved cell-based products it is

Quiz me this…..! What new technology emerged in the 1970s that truly changed the world?…. Certainly, you immediately thought of ‘the computer’ in your top 5

…………. catching up on recent FDA approvals The FDA recently approved a new therapy, Crenessity (crinecerfont) from Neurocrine Biosciences, Inc., to be used together with glucocorticoids

…………………. catching up on recent FDA approvals The FDA recently approved a new infused therapy, Bizengri (zenocutuzumab-zbco) from Merus N.V., indicated for adults with pancreatic adenocarcinoma

The FDA recently approved a biosimilar, Yesintek (Ustekinumab-kfce) from Biocon Biologics Ltd, as a biosimilar to the reference product, Stelara (Ustekinumab).   This approval is the

……….. catching upon FDA approvals The FDA recently approved a new ORAL specialty therapy, Revuforj (revumenib) from Syndax Pharmaceuticals, for the treatment of relapsed or

………… catching up on FDA approvals The FDA recently approved a new infused therapy, Aucatzyl (obecabtagene autoleucel) from Autolus Inc., indicated for the treatment of adults

The NHIA recently released a comprehensive list of therapies that have been routinely dispensed by home infusion providers. This comprehensive grouping, especially by therapeutic category and

The FDA recently approved a new infused therapy, Vyloy (zolbetuximab-clzb) – in combination with fluoropyrimidine and platinum-containing chemotherapy – from Astellas Pharma Inc., for the

So, how much do you know about bispecific therapy? Can you even offer a passing definition? Well, read on dear reader….. and learn enough to